Additionally, the analysis of three placebo-controlled RCTs indicated comparable withdrawal rates for aripiprazole (10.1%) and placebo (11.5%), emphasizing that, according to the available evidence, the primary consideration for reducing prolactin concentrations in schizophrenia patients with hyperprolactinemia is the addition of aripiprazole. This evidence concerns the gene PRL and hyperprolactinemia.